Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
We know that the market makers follow social media and the boards.
Would not be hard to have someone on the boards trying to sway opinion.
Johhnybig and the butler on advfn spent weeks trashing the shares.The then vanished.
Suddenly this liam booth/lbo on advfn arrived playing the same tactics?
Coincidence? You decide.
Has anyone looked at the trading volumes since the initial rally?
Where is are the sales to counter the shares that were sold up to higher levels?
Buys/sells were over 2 to 1
Isn't it odd how liambooth/odyseus has been on an intense campaign.
He then told us actually he is a shareholder/.
Oh dear
Professor Burnett commented: "In my humble opinion and as an expert in the field of erectile dysfunction management, I am very supportive of MED3000 and do believe that it offers an important and valid addition to the armamentarium of treatments we can offer our patients for erectile dysfunction. I am very pleased to support Futura Medical in the further clinical investigatiessor of Urology, Johns Hopkins School of Medicine, Brady Urological Institute. Professor Burnett is also a past President of the Sexual Medicine Society.on of this novel topical treatment."
world-renowned Professor Arthur Burnett, MD, MBA, FACS, Distinguished Professor of Urology, Johns Hopkins School of Medicine, Brady Urological Institute. Professor Burnett is also a past President of the Sexual Medicine Society.
Most amusing that liambooth/odyseus reckons he knows better than the worlds top ED experts.
If ky jelly had an impact of the millioins of men suffering ED he believes those in the field have missed it.
Dumb and dumber
"A total of £30m of EU milestones
and £60m of US milestones related to
MED2005, receivable across filing, approval
and OTC conversion."
Simger N+1 reckoned that Futura would get up t 0 £90 million in upfront and milestone payments alone.
What is really interesting is the fact that Med3000 will head straight to OTC,meaning those payments will likely be received far quicker than previously anticipated.
That is all on top of a likely 20% royalty rate.
Big big numbers
All formulations tested in FM57, including MED3000, have demonstrated positive and statistically significant efficacy results against baseline data together with excellent safety profile. MED3000 will be of high interest to the Medical Community for those patients who are seeking a very rapid onset of action and a very low side-effect profile. It will likely find use in the substantial number of patients, especially those with ED of a mild to moderate nature and those patients who are contraindicated for use with existing products.
Dr Yacov Reisman
Consultant Urologist and past president of the European Society of Sexual Medicine
Or that
The efficacy of MED3000 is remarkable and approaches the efficacy of current first line therapy but with significantly lower adverse events. With topical application, it will be of particular appeal to patients who want a fast onset of action. Lack of drug interactions with prescription products will enable the product to be used with other medications such as nitrates and other cardiovascular drugs. It can also be used in conjunction with other ED products to improve overall efficacy to patients. As such MED3000 will be of great interest to the medical community.”
Professor David Ralph
Consultant Urologist at University College London and past president of the European Society of Sexual Medicine
Or that
Professor Burnett commented: "In my humble opinion and as an expert in the field of erectile dysfunction management, I am very supportive of MED3000 and do believe that it offers an important and valid addition to the armamentarium of treatments we can offer our patients for erectile dysfunction. I am very pleased to support Futura Medical in the further clinical investigation of this novel topical treatment."
world-renowned Professor Arthur Burnett, MD, MBA, FACS, Distinguished Professor of Urology, Johns Hopkins School of Medicine, Brady Urological Institute. Professor Burnett is also a past President of the Sexual Medicine Society.
It doesn't come much better than that
"As such it is possible to
see MED3000 gaining a 20% market share from these patients alone."
That is effectively admitting that their forecasts are conservative.A tone also implied by Trinity Delta who stated
"Our risk-adjusted DCF model continues to employ conservative assumptions."
"It is worth mentioning that in addition to going head-to-head with the PDE-5s,
there are a couple of easy wins for MED3000. Firstly, 15-20% of men are
contraindicated (cannot be prescribed) to PDE-5s as they are on nitrate, antihypertensies and a range of other therapies. In addition, about 50% of men
prescribed PDE-5s abandon therapy within a year. As such it is possible to
see MED3000 gaining a 20% market share from these patients alone."
(source Liberum)
20% peak patient share possible
"Currently, the majority of patients that are diagnosed with ED are started on
PDE-5 inhibitors, the oral class of drugs that includes Viagra and Cialis. We
believe that MED3000 should be positioned as a first line therapy before the
orals given. It is likely to have a better safety profile, is more convenient and
has a more rapid onset of action, which with the local administration is likely
to result in a more natural experience for the patient. This means that
MED3000 could genuinely target the 400 million men in the US and EU5 that
have ED.
We assume that in practice it is only men with mild/moderate disease that will
be directed to MED300"
(source Liberum)
If one simply take the EU side,forecast peak annual sales of £280 million,that alone would bring in £56 million a year in royalties to Futura.
Then there is the rest of the world and the USA.
The potential here is quite extraordinary.
Now the liambooth/lbo who laughbale is claimin go be a shareholder after 82 posts of drivel is trying yet another angle.
" a topical spray that combines Futura's DermaSys® AquaFree delivery system with a mild topical anaesthetic. EPIC is designed to delay male ejaculation and to take effect quickly."
The product is totally different and was sprayed on.It was to prevent premature ejaculation and was tested for such.It also contained a mild anaesthetic.
Med3000 is for those gents that have a flacid ***** that can't get an erection.It is a gel applied to the tip of the *****
His desperation is pathetic.
Sounds like Odyseus has reincarnated.
If anything I could go after you for defamation and libel,so I would tread carefully old chap.
There you go threatening again.
I stand by all my posts and have absolutely nothing to worry about
Agree.78 posts trashing the co only to reveal the BOMBSHELL today that he actually owns shares.!!!
Which planet is he on again?
"Market makers are the subject of much mystique. Are they human? Yes. Do they make money at your expense? Probably. Do they monitor Twitter and bulletin boards? Almost certainly. Wouldn’t you?"
Oh here we go now he claims to be invested.
Laughable if it wasn't such blatant bs
Market Makers’
Methods of Stock
Manipulation
https://www.imanet.org/-/media/4c6c7650a0024853a1c61963d7865649.a
The sudden appearance of liambooth and lbo on advfn had an odd coincidence.